Stocks Health care STRO
NASDAQ · Health careSutro Biopharma, Inc. (STRO)
Sutro Biopharma, Inc. brought in $45.7M of revenue over the twelve months to June 30, 2026, down 56.3% from a year earlier. It posted a net loss of $180.6M. At June 30, 2026 it held $54.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
What Sutro Biopharma, Inc. does
Sutro Biopharma, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker STRO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $102.5M | -$191.1M | -$22.49 | n/a |
| 2024 | $62M | -$227.5M | -$29.40 | n/a |
| 2023 | $153.7M | -$106.8M | -$17.68 | n/a |
| 2022 | $67.8M | -$119.2M | -$23.34 | n/a |
| 2021 | $61.9M | -$105.5M | -$22.75 | n/a |
| 2020 | $42.7M | -$32.1M | -$9.83 | n/a |
Latest SEC filings
What Sutro Biopharma, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026Quarterly report 10-Q · period to June 30, 2026
- August 12, 2026
- July 30, 2026Passive stake (5% or more) SCHEDULE 13G
- June 8, 2026
- May 15, 2026Passive stake (5% or more) SCHEDULE 13G
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 14, 2026Quarterly report 10-Q · period to March 31, 2026
- May 14, 2026
Questions about STRO
What does Sutro Biopharma, Inc. do?
Sutro Biopharma, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker STRO.
Is Sutro Biopharma, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $180.6M on revenue of $45.7M.
How much revenue does Sutro Biopharma, Inc. make?
Over the twelve months to June 30, 2026 Sutro Biopharma, Inc. reported revenue of $45.7M. That is 56.3% less than a year earlier.
When did Sutro Biopharma, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 22, 2026.
Similar companies
Follow STRO
Get an email when Sutro Biopharma, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow STRO: get an email when it filesWhere the numbers come from
Financial figures are the values Sutro Biopharma, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.